JP2020063263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020063263A5 JP2020063263A5 JP2019217044A JP2019217044A JP2020063263A5 JP 2020063263 A5 JP2020063263 A5 JP 2020063263A5 JP 2019217044 A JP2019217044 A JP 2019217044A JP 2019217044 A JP2019217044 A JP 2019217044A JP 2020063263 A5 JP2020063263 A5 JP 2020063263A5
- Authority
- JP
- Japan
- Prior art keywords
- hematopoietic stem
- cells
- pge
- activity
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 23
- 239000000203 mixture Substances 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 150000003180 prostaglandins Chemical class 0.000 claims 6
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 3
- QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 238000002659 cell therapy Methods 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023001015A JP2023052244A (ja) | 2008-11-06 | 2023-01-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11201808P | 2008-11-06 | 2008-11-06 | |
| US61/112,018 | 2008-11-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017195168A Division JP2018048156A (ja) | 2008-11-06 | 2017-10-05 | 造血幹細胞の生着手順を強化するための材料および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023001015A Division JP2023052244A (ja) | 2008-11-06 | 2023-01-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020063263A JP2020063263A (ja) | 2020-04-23 |
| JP2020063263A5 true JP2020063263A5 (cg-RX-API-DMAC7.html) | 2020-09-03 |
Family
ID=42153284
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534934A Expired - Fee Related JP5846915B2 (ja) | 2008-11-06 | 2009-11-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2015134076A Expired - Fee Related JP6632822B2 (ja) | 2008-11-06 | 2015-07-03 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2017195168A Withdrawn JP2018048156A (ja) | 2008-11-06 | 2017-10-05 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2019217044A Withdrawn JP2020063263A (ja) | 2008-11-06 | 2019-11-29 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2023001015A Pending JP2023052244A (ja) | 2008-11-06 | 2023-01-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534934A Expired - Fee Related JP5846915B2 (ja) | 2008-11-06 | 2009-11-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2015134076A Expired - Fee Related JP6632822B2 (ja) | 2008-11-06 | 2015-07-03 | 造血幹細胞の生着手順を強化するための材料および方法 |
| JP2017195168A Withdrawn JP2018048156A (ja) | 2008-11-06 | 2017-10-05 | 造血幹細胞の生着手順を強化するための材料および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023001015A Pending JP2023052244A (ja) | 2008-11-06 | 2023-01-06 | 造血幹細胞の生着手順を強化するための材料および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US9107909B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3031907B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP5846915B2 (cg-RX-API-DMAC7.html) |
| CN (4) | CN102245758A (cg-RX-API-DMAC7.html) |
| AU (4) | AU2009313290B2 (cg-RX-API-DMAC7.html) |
| CA (3) | CA3203374A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2845641T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3031907T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010054271A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201804932B (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8883507B2 (en) | 2005-10-18 | 2014-11-11 | The Regents Of The University Of Colorado | Conditionally immortalized long-term hematopoietic stem cells and methods of making and using such cells |
| SG10201803982TA (en) | 2008-05-16 | 2018-07-30 | Taiga Biotechnologies Inc | Antibodies and processes for preparing the same |
| US8784825B2 (en) | 2008-08-28 | 2014-07-22 | Taiga Biotechnologies, Inc. | Modulators of MYC, methods of using the same, and methods of identifying agents that modulate MYC |
| EP3031907B1 (en) | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| US10813917B2 (en) | 2009-12-11 | 2020-10-27 | Medregen, Llc | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents |
| CN103167876B (zh) * | 2010-08-12 | 2016-08-31 | 菲特治疗公司 | 改进的造血干细胞和祖细胞疗法 |
| PL2663313T3 (pl) * | 2011-01-13 | 2019-01-31 | SciPharm S.à r.l. | Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych |
| CA2850484C (en) | 2011-09-30 | 2021-01-26 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| EP2785350B1 (en) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Improved methods of treating ischemia |
| CN104066837B (zh) | 2011-12-02 | 2020-12-08 | 菲特治疗公司 | 增强的干细胞组合物 |
| WO2013130499A1 (en) * | 2012-02-29 | 2013-09-06 | University Of Virginia Patent Foundation | Compositions and methods for cxcr4 signaling and umbilical cord blood stem cell engraftment |
| WO2014015318A1 (en) * | 2012-07-19 | 2014-01-23 | Bluebird Bio, Inc. | Soluble compounds for improved gene therapy methods |
| JP6285930B2 (ja) * | 2012-07-20 | 2018-02-28 | タイガ バイオテクノロジーズ,インク. | 造血コンパートメントの再構築及び自家再構築の増進 |
| US20150216903A1 (en) * | 2012-08-10 | 2015-08-06 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| WO2014134539A1 (en) | 2013-02-28 | 2014-09-04 | President And Fellows Of Harvard College | Methods and compositions for mobilizing stem cells |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| US9943545B2 (en) * | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| EP4091609A1 (en) | 2013-04-29 | 2022-11-23 | Medregen, LLC | Wound healing via autologous stem cell mobilization |
| KR101489861B1 (ko) * | 2013-05-07 | 2015-02-05 | 경북대학교 산학협력단 | Amd3100을 포함하는 골질환 예방 또는 치료용 조성물 |
| CA2974903A1 (en) | 2015-01-26 | 2016-08-04 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| CN104774806B (zh) * | 2015-04-09 | 2019-02-15 | 广州赛莱拉干细胞科技股份有限公司 | 一种胎盘造血干细胞的制备方法 |
| BR112018001232A2 (pt) | 2015-07-21 | 2018-09-25 | The Children's Medical Center Corporation | pd-l1 que expressa células-tronco hematopoéticas e usos |
| CN108883136A (zh) | 2016-02-12 | 2018-11-23 | 蓝鸟生物公司 | Vcn增强子组合物及其使用方法 |
| KR20250134722A (ko) | 2016-02-12 | 2025-09-11 | 블루버드 바이오, 인코포레이티드. | Vcn 인핸서 조성물 및 이의 사용 방법 |
| WO2017147610A1 (en) * | 2016-02-26 | 2017-08-31 | President And Fellows Of Harvard College | Highly engraftable hematopoietic stem cells |
| US20200224165A1 (en) * | 2016-07-22 | 2020-07-16 | Senlin Li | Methods and compositions for rejuvenation |
| US10583156B2 (en) | 2016-12-02 | 2020-03-10 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| AU2018212854B2 (en) | 2017-01-27 | 2024-06-20 | Children's Hospital Medical Center | Methods of enhancing engraftment activity of hematopoietic stem cells |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| US11213546B2 (en) | 2017-09-07 | 2022-01-04 | Emory University | Methods to mobilize tissue resident cells for adoptive t cell therapy |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| FR3074189A1 (fr) * | 2017-11-30 | 2019-05-31 | Assistance Publique - Hopitaux De Paris | Methode de generation de greffons de cellules souches hematopoietiques |
| CN108404112B (zh) * | 2018-04-01 | 2020-05-12 | 北京诺赛启研再生医学研究院有限公司 | 提高造血干细胞归巢及植入率的方法及其试剂 |
| EP3647413A1 (en) * | 2018-10-31 | 2020-05-06 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) | Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation |
| EP3952909A4 (en) | 2019-04-08 | 2023-06-07 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR CRYOPRESERVING IMMUNE CELLS |
| SG11202112529WA (en) | 2019-05-14 | 2021-12-30 | Taiga Biotechnologies Inc | Compositions and methods for treating t cell exhaustion |
| JP7543395B2 (ja) | 2020-03-31 | 2024-09-02 | デンカ株式会社 | アルミナ粉末、樹脂組成物、及び放熱部品 |
| CN116509834B (zh) * | 2023-01-20 | 2025-05-13 | 东北师范大学 | 化合物在制备造血干/祖细胞增殖和损伤修复药物中的应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399493A (en) * | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| JPH08205860A (ja) * | 1994-01-21 | 1996-08-13 | Usa Government | 造血細胞の膨大化および移植方法 |
| US5928638A (en) * | 1996-06-17 | 1999-07-27 | Systemix, Inc. | Methods for gene transfer |
| CA2462628C (en) * | 2001-10-02 | 2019-08-20 | Institut Clayton De La Recherche | Restricted expression lentiviral vectors |
| EP1461087A1 (en) * | 2001-12-06 | 2004-09-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| EP1471818A4 (en) * | 2002-02-04 | 2007-03-28 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR TREATING HEMATOLOGICAL DISEASES USING 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137 , 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 OR 13249 MOLECULES |
| JP4865541B2 (ja) | 2003-04-08 | 2012-02-01 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | 化学誘引物質に対する増大させた感受性を有する幹細胞およびそれを産生および使用する方法 |
| IL158868A0 (en) | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| WO2006001463A1 (ja) * | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | S1p受容体結合能を有する化合物およびその用途 |
| US20080021078A1 (en) | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
| WO2007041511A2 (en) * | 2005-09-30 | 2007-04-12 | New York University | Hematopoietic progenitor kinase 1 for modulation of an immune response |
| JP2007099724A (ja) | 2005-10-06 | 2007-04-19 | Shizuoka Prefecture | スルファチドを標的とした抗ウイルス剤 |
| US8076315B2 (en) * | 2005-10-14 | 2011-12-13 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
| EP1999255A2 (en) * | 2006-03-24 | 2008-12-10 | The Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| WO2007148332A1 (en) | 2006-06-22 | 2007-12-27 | Yeda Resaerch And Development Co. Ltd | Catecholamine receptor modulation |
| EP3824885A1 (en) | 2006-10-20 | 2021-05-26 | Children's Medical Center Corporation | Method to enhance tissue regeneration |
| EP2094839B1 (en) * | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion of hematopoietic stem cells |
| US8598328B2 (en) | 2006-12-13 | 2013-12-03 | National University Corporation Nagoya University | Tol1 factor transposase and DNA introduction system using the same |
| EP3031907B1 (en) | 2008-11-06 | 2021-01-06 | Indiana University Research and Technology Corporation | Materials and methods to enhance hematopoietic stem cells engraftment procedures |
| EP3533445A1 (en) | 2009-03-19 | 2019-09-04 | Fate Therapeutics, Inc. | Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same |
| CA2850484C (en) | 2011-09-30 | 2021-01-26 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
-
2009
- 2009-11-06 EP EP16153526.5A patent/EP3031907B1/en not_active Revoked
- 2009-11-06 CA CA3203374A patent/CA3203374A1/en active Pending
- 2009-11-06 CN CN2009801495225A patent/CN102245758A/zh active Pending
- 2009-11-06 EP EP09825528.4A patent/EP2362733B1/en not_active Not-in-force
- 2009-11-06 PT PT161535265T patent/PT3031907T/pt unknown
- 2009-11-06 CA CA3012803A patent/CA3012803C/en active Active
- 2009-11-06 JP JP2011534934A patent/JP5846915B2/ja not_active Expired - Fee Related
- 2009-11-06 ES ES16153526T patent/ES2845641T3/es active Active
- 2009-11-06 CA CA2742876A patent/CA2742876C/en active Active
- 2009-11-06 WO PCT/US2009/063654 patent/WO2010054271A1/en not_active Ceased
- 2009-11-06 US US13/128,074 patent/US9107909B2/en active Active
- 2009-11-06 CN CN201710777353.6A patent/CN107523587A/zh active Pending
- 2009-11-06 CN CN201710777354.0A patent/CN107630001A/zh active Pending
- 2009-11-06 EP EP20195600.0A patent/EP3824884A1/en not_active Withdrawn
- 2009-11-06 AU AU2009313290A patent/AU2009313290B2/en not_active Ceased
- 2009-11-06 CN CN201810232658.3A patent/CN108379292A/zh active Pending
-
2014
- 2014-06-27 US US14/318,167 patent/US10213460B2/en active Active
-
2015
- 2015-03-04 US US14/638,676 patent/US9675641B2/en not_active Expired - Fee Related
- 2015-07-03 JP JP2015134076A patent/JP6632822B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-21 AU AU2016206316A patent/AU2016206316C1/en not_active Ceased
-
2017
- 2017-05-11 US US15/592,375 patent/US11241454B2/en not_active Expired - Fee Related
- 2017-10-05 JP JP2017195168A patent/JP2018048156A/ja not_active Withdrawn
-
2018
- 2018-07-23 ZA ZA2018/04932A patent/ZA201804932B/en unknown
- 2018-10-08 AU AU2018241208A patent/AU2018241208B2/en not_active Ceased
-
2019
- 2019-11-29 JP JP2019217044A patent/JP2020063263A/ja not_active Withdrawn
-
2020
- 2020-08-21 AU AU2020220191A patent/AU2020220191B2/en not_active Ceased
-
2021
- 2021-12-14 US US17/550,737 patent/US20220313735A1/en not_active Abandoned
-
2023
- 2023-01-06 JP JP2023001015A patent/JP2023052244A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2401608T3 (es) | Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes | |
| MY197586A (en) | Adenovirus armed with bispecific t cell engager (bite) | |
| SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
| CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
| ES2900560T3 (es) | Terapia génica. | |
| JP2018184448A5 (cg-RX-API-DMAC7.html) | ||
| MX2025013445A (es) | Generacion de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitucion de genes dirigida al higado | |
| MY209906A (en) | Lipid nanoparticle formulations of non-viral, capsid-free dna vectors | |
| MX2021001292A (es) | Metodos para la modificacion genica de celulas hematopoyeticas. | |
| MX2022010363A (es) | Formulaciones clinicas. | |
| MX2024012761A (es) | Terapia genica con el atanogeno 3 asociado a linfoma de celulas b 2 (bag3) utilizando el vector aav | |
| MX2020005663A (es) | Terapia genica para mucopolisacaridosis iii a. | |
| WO2021081457A3 (en) | Methods and agents for enhancing t cell therapies | |
| Zhou et al. | IFNα‐expressing amniotic fluid‐derived mesenchymal stem cells migrate to and suppress HeLa cell‐derived tumors in a mouse model | |
| Petersen et al. | Efficient transduction of equine adipose-derived mesenchymal stem cells by VSV-G pseudotyped lentiviral vectors | |
| JP2019068814A5 (cg-RX-API-DMAC7.html) | ||
| Perlea et al. | Phenotype heterogeneity in dental pulp stem niches | |
| CA3217059A1 (en) | Compositions for improving the transduction of cells by viral vectors | |
| Yusoff et al. | A comparison of culture characteristics between human amniotic mesenchymal stem cells and dental stem cells | |
| Aizenshtadt et al. | Charachterization of umbilical cord mesenchymal stromal cells during long-term expansion in vitro | |
| ATE481495T1 (de) | Adenovirusvektor | |
| Hoetzenecker | Step by step toward the summit | |
| George et al. | Editing of highly homologous gamma-globin genes by nickase deficient Base Editor mitigates large intergenic deletions | |
| Nicholson et al. | 118. Inhibition of Hepatitis B Virus Replication In Vivo Following Delivery of Antiviral TALENs With Recombinant Adeno-Associated Viral Vectors | |
| MY190213A (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues |